רווח תפעולי לפני ניכוי פחת: Dianthus Therapeutics, Inc. (DNTH)

The stability of Dianthus Therapeutics (DNTH) relies on the expansion of DNTH-103 complement inhibitors within the rare disease segment. This chart of EBITDA_Co confirms this trajectory, where the 0.00 metric determines this level. However, the business is constrained by strict patent barriers and high development costs, while the absence of current sales leads to a gradual depletion of the company's cash reserves.

The development of self-administration antibodies at Dianthus Therapeutics (DNTH) is directly reflected in the EBITDA chart. This metric captures the actual cash flow from core operations, excluding the impact of taxes and asset depreciation. Investors can see the net result of cash generation, stripped of accounting write-downs. Inelastic demand for complement inhibitors provides the company with significant pricing power, transforming product uniqueness into stable operational efficiency for the business.